

CURRICULUM VITAE

Curtis A. Hamburg, M.D., F.A.C.C.

Baptist Medical Arts Building
8950 N. Kendall Drive, Suite 601
Miami, Florida 33176
(305) 279-4500

Date of Birth:

May 27, 1953

Place of Birth:

New York, New York

Marital Status:

Married; Four children -

Ages 26, 24, 20, 2, 1

PROFESSIONAL AFFILIATION:

Staff Physician
Baptist Hospital of Miami
8900 N. Kendall Drive
Miami, Florida 33176

Staff Physician
South Miami Hospital
6200 SW 73rd Ave
Miami, Florida 33143

CURRENT LICENSE:

National Board of Medical Examiners
License - Number 0036664 - Florida

EDUCATION:

Cornell University; 1970-1974
Ithaca, New York

Rutgers Medical School; 1974-1976
Piscataway, New Jersey

Albert Einstein College of Medicine; 1976-1978
Bronx, New York

DEGREES:

Bachelor of Arts, Cum Laude; 1974
Cornell University
Major: Biochemistry

Doctor of Medicine; 1978
Albert Einstein College of Medicine

PROFESSIONAL TRAINING:

Internal Medicine (Internship); July 1978 - June 1979
Bronx Municipal Hospital Center
Bronx, New York

Internal Medicine (Residency); July 1979 - June 1981
Bronx Municipal Hospital Center
Bronx, New York

FELLOWSHIP:

Cardiology; July 1981 - June 1983
University of Miami School of Medicine
Miami, Florida

INVESTIGATIONS - RESEARCH:

Cardiovascular Research Center of South Florida

NYCOMED Study. Principal Investigator. This is a phase III multicenter study of left ventricular endocardial border delineation and ejection fraction by contrast-enhanced echocardiography using NC100100 powder for injection administered intravenously to low-echogenic subjects.

LINK Coagulation Study PNT3 (Medical Research International). Principal Investigator. The purpose of this study is to assess the feasibility of using saliva and urine as a test medium to determine the state of anticoagulation imparted by Warfarin therapy.

INVEST (Knoll Pharmaceuticals). Investigator. This is an international clinical trial comparing a calcium antagonist (Verapamil SR) with a non-calcium antagonist treatment strategy (Atenolol) for the control of hypertension in patients with coronary artery disease.

SPORTIF – An anticoagulation study in patients with atrial fibrillation .

ACTIVATE (SankyoPharma Development) A Randomized, Double-Blind placebo Controlled Study of the Efficacy and Safety of the ACAT inhibitor CS-505 versus Placebo for Reducing the Progression of Atherosclerosis in Subjects with Known Coronary Artery Disease Using Ultrasound (IVUS).

EVEREST (Otsuka Pharmaceuticals) A Randomized, Double-blind Placebo-controlled Study to Evaluate the Long Term Efficacy and Safety of Oral Tolvaptan Tablets in Subjects Hospitalized with Worsening Congestive Heart Failure.

CHARISMA (Sanofinsynthelabo and Bristol Myers Squibb Co.) Clopidogrel For High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance.

CP-529, 414 (Pfizer) A Randomized, Double-blind Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin in Patients with Angiographically Documented Coronary Artery Disease.

LUNAR (AstraZeneca) A 12-Week, Randomized, Open-Label, 3-Arm, Parallel Group, Multicenter, Phase IIIb Study Comparing the Efficacy and Safety of Rosuvastatin 20 mg and 40 mg with that of Atorvastatin 80 mg in Subjects with Acute Coronary Syndromes.

INVESTIGATIONS – RESEARCH (cont):

NEB 302 (Bertek Pharmaceuticals) A Double-blind, Multi-Center, Randomized, Placebo-Controlled, Parallel Group Dosing Study Evaluating the Effects of Nebivolol on Blood Pressure in Patients with Mild to Moderate Hypertension.

NEB 306 (Bertek Pharmaceuticals) A Multi-Center, Parallel Group Extension Study to Determine the Safety and Efficacy of Long-Term Nebivolol Exposure in Patients with Mild to Moderate Hypertension.

NEB 323 (Bertek Pharmaceuticals) A Multi-Center, Open Extension Study to Assess the Safety and Efficacy of Long-Term Nebivolol Exposure in Patients with Mild to Moderate Hypertension.

COMPELL (Kos Pharmaceuticals) An Open-Label, Comparative Efficacy Evaluation of Lipid Levels when Treated with Niaspan and Statin or Other Lipid-Modifying Therapies.

MDT3-003 (Labopharm) A Four-Arm Study Comparing the Analgesic Efficacy and Safety of Tramadol HCl Once a day 100, 200 and 300 mg Versus Placebo for the Treatment of Pain due to Osteoarthritis of the Knee.

PRACTICE:

Cardiology/Internal Medicine; 1983 - 1997
Curtis A. Hamburg, M.D., F.A.C.C.
8950 N. Kendall Drive, Suite 302
Miami, Florida 33176

Cardiology/Internal Medicine; March 1997 – June 1999
Miami Cardiology Group
8950 N. Kendall Drive, Suite 601
Miami, Florida 33176

SPECIALTY CERTIFICATION:

Diplomate; American Board of Internal Medicine - September 1981
Diplomate; American Board of Internal Medicine, Subspecialty
Board in Cardiovascular Diseases - November 1983

HONORS AND AWARDS:

Cum Laude, Cornell University; June 1974
MED - Premedical Honorary, Cornell University; June 1973
AOA - Medical School Honorary, Albert Einstein College
of Medicine; June 1977
Harry Botwick Award for Superior Performance as a
Cardiology Fellow, University of Miami; 1982 - 1983
Fellow, American College of Cardiology; September 1985

APPOINTMENTS:

Faculty Member; July 1982 - June 1983
**Tutorial Course in Coronary Care for
the Practicing Physician**
University of Miami School of Medicine
Miami, Florida

Voluntary Faculty Member; June 1994 - Present
Preceptor Program
University of Miami School of Medicine
Miami, Florida

Medical Director; June 1998 - Present
Echocardiography Lab
Miami Cardiovascular Institute at
Baptist Hospital of Miami
Miami, Florida

MEDICAL SOCIETY MEMBERSHIP:

Member; American Heart Association
Fellow; American College of Cardiology

HOSPITAL APPOINTMENTS:

Baptist Hospital of Miami
Miami, Florida

South Miami Hospital
Miami, Florida

REFERENCES:

Furnished Upon Request